Global 3D Cell Culture Technologies Market

Cell culture consumables and equipment are designed to aid scientists in growing new cells in the culture media for drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. The main products in cell culture consumables and equipment are consumables and instruments. The cell culture instruments involve the various instruments that are required for cell culture in the cell culture laboratory. The various instruments used in cell culture are cell culture vessels, bioreactors, biosafety cabinets, carbon dioxide incubators, and centrifuge and consumables are media, sera, and reagents. The applications involved are vaccination, toxicity testing, cancer research, drug screening and development, recombinant products, stem cell technology, regenerative medicine, and others that are used by end-users such as industrial, biotechnology, agriculture, and others. The cell culture consumables and equipment market research report is one of a series of new reports from The Business Research Company that provides cell culture consumables and equipment market statistics, including cell culture consumables and equipment industry global market size, regional shares, competitors with a cell culture consumables and equipment market share, detailed cell culture consumables and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cell culture consumables and equipment industry. This cell culture consumables and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cell culture consumables and equipment market grew from $10.99 billion in 2022 to $12.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cell culture consumables and equipment market is expected to grow from $17.98 billion in 2027 at a CAGR of 10.4%. An increase in the prevalence of chronic diseases is driving the growth of the cell culture consumables and equipment market. Chronic diseases such as cancer, diabetes, heart diseases, obesity, and hypertension are growing rapidly. A few chronic diseases are caused due to loss or damage of certain types of cells. Such diseases can be cured by replacing the destroyed cells with new ones that are produced by pluripotent stem cells, using cell culture consumables and equipment. So, with the rising incidence of chronic diseases, there is an increased need for such equipment that can produce new cells outside the natural environment, thus driving the growth of this market. For example, according to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. Contamination of cell culture is the most prominent factor restricting the growth of cell culture consumables and equipment market. Contaminated culture is the presence of non-living substances or unwanted foreign microorganisms that have undesirable effects on the cell culture. Using contaminated culture cells has several negative consequences on the users and thus hampers the growth of this market. For example, an article published on MedCrave, stated that Mycoplasma is one of the most common and difficult to detect contaminants. The article also highlighted the results of a study on fibroblasts and keratinocyte cell lines that showed 32.35% of contamination, out of which 17.65% were mycoplasma contaminated cultures, followed by fungal (8.82%) and bacterial (5.88%) contaminants. Hence, the high risk associated with cell culture techniques poses a threat to the growth of the cell culture consumables and equipment market. Companies in cell culture consumables and equipment are investing more in 3D cell culture for its new and advantageous features. 3D cell culture may be defined as the culture of living cells within micro-assembled devices and supports that present a three-dimensional structure and are used to replicate a tissue or an organ in an artificial environment by allowing the cells to interact with the surroundings in all three directions. 3D cell cultures are more relevant with a higher degree of structural complexity and maintain the steady-state for more time as compared to 2D cell cultures. In August 2021, Amerigo Scientific, a US-based manufacturer of biomedical and life sciences products, launched #D cell cultures for research purposes. FDA regulates cell culture consumables and equipment in the U.S. Under title 21, Sec 864.2240. For cell and tissue culture equipment, the FDA states that if the equipment is not labelled or mentioned as sterile, it would be removed from the good manufacturing practises of the quality system. Additionally, each manufacturing unit should maintain procedures to receive, review, and evaluate complaints. These procedures require consistency and punctuality, along with the documentation of the receipts. Therefore, these regulatory standards improve the safety and efficacy of instruments and consumables used during cell culture processes. In July 2021, Sartorius, a Germany-based laboratory instrument manufacturer, acquired Xell AG for an undisclosed amount. The acquisition would expand Sartorius’ current media offering and other cell culture products. Xell AG is a Germany-based cell culture specialist. Major players in the cell culture consumables and equipment market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Lonza, HiMedia Laboratories, Agilent Technologies, and PromoCell GmbH. North America was the largest region in the cell culture consumables and equipment market in 2022. Western Europe was the second largest region in the global cell culture consumables and equipment market report. The regions covered in the global cell culture consumables and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell culture consumables and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell culture consumables and equipment market consists of sales of flasks, tubes, dishes or cryovials, serological pipettes or centrifugation tubes, bottles, cell scrapers, strainers, coverslips, and inserts. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global cell culture consumables and equipment market is segmented - 1) By Product: Consumables, Instruments 2) By End User: Industrial, Biotechnology, Agriculture, Other End Users 3) By Application: Vaccination, Toxicity testing, Cancer Research, Drug Screening and Development, Recombinant Products, Stem cell technology, Regenerative Medicine, Other End Users 4) By Consumables: Media, Sera, Reagents 5) By Instruments: Cell Culture Vessels, Bioreactors, Biosafety Cabinets, Carbon Dioxide Incubators, Centrifuges

Single-use assemblies refer to single-use components that ensure a sterilized fluid flow of pharmaceutical products. These are fully completed process systems that are customer-specific, ready-to-use, all-in-one solutions composed of various plastic parts that are integrated into a single unit. Single-use assemblies offer the benefit of fewer cross-contamination and leakage concerns, fewer production interruptions, lower costs, and many more. The single-use assemblies are used to connect medical and laboratory instruments and equipment. The main types of single-use assemblies market products are filtration assemblies, bag assemblies, bottle assemblies, and mixing system assemblies. Filtration assemblies are used for tissue culture media, biological fluids, High-Performance Liquid chromatography (HPLC), and other aqueous solutions vacuum filtered. Filtration assemblies refer to the removal of particulate matter from the water via passage through porous media. The solutions are standard solutions and customized solutions. The various applications are cell culture and mixing, filtration, storage, sampling, and fill-finish application. The various end users are biopharmaceutical and pharmaceutical companies, contract research and contract manufacturing organizations, and academic and research institutes. The single-use assemblies market research report is one of a series of new reports from The Business Research Company that provides single-use assemblies market statistics, including single-use assemblies industry global market size, regional shares, competitors with an single-use assemblies market share, detailed single-use assemblies market segments, market trends and opportunities, and any further data you may need to thrive in the single-use assemblies industry. This single-use assemblies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global single-use assemblies market size grew from $4.13 billion in 2022 to $4.81 billion in 2023 at a compound annual growth rate (CAGR) of 16.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The single-use assemblies market size is expected to grow to $10.81 billion in 2027 at a CAGR of 22.5%. An increase in demand for biopharmaceuticals and a rise in life science R&D are expected to propel the growth of single-use assemblies. Biopharmaceuticals are sophisticated medicines produced from living cells or organisms and are frequently created using cutting-edge biotechnological techniques. Single-use systems are utilized in biopharmaceutical manufacturing. Increased lie science R&D spending is also a contributor to the development of new drugs. For instance, according to the International Federation of Pharmaceutical Manufacturers and Association (IFPMA), a Switzerland-based trade association of pharmaceutical companies, in 2020, there is an increase in the development of drugs in specific disease areas such as for cancer- 2740 new drugs were developed. For immunology, 1535 new drugs were developed and for Infectious diseases, 1213 new drugs were developed. As of 2021, there are new 50 medicines and vaccines are developed for HIV. Further, according to the Association of Medical Research Charities (AMRC), a UK-based association of medical and health research charities increased its R&D spending from £1.3 billion to £1.9 billion in 2020. Also, UK foreign direct investment in life sciences reached £510 million. Therefore, an increase in demand for biopharmaceuticals and a rise in life science R&D are driving the growth of single-use assemblies. Technological advancement is a key trend gaining popularity in the single-use assemblies market. Major companies operating in the market are introducing new technologies such as the Thermo Scientific HyPeak chromatography system which is a single-use chromatography system to sustain their position in the market. For instance, in October 2021, Thermo Fisher Scientific, a US-based manufacturer of scientific instruments, launched the Thermo Scientific HyPeak chromatography system, which is a single-use chromatography system. That helps to flows ranging from one liter per hour to 1980 liters per hour. That had unique features like zero dead-leg and a ring flush valve manifold that helps to improve product yield and operation. In June 2021, Avantor Inc., a US-based science, chemical, and materials company, acquired RIM Bio for an undisclosed amount. Through this acquisition, by extending Avantor’s single-use production, distribution, and cleanroom capabilities to the AMEA area, the addition of RIM Bio enables Avantor to better serve their customers and strengthens Avantor's position to seize long-term opportunities in the expanding, international bioproduction market RIM Bio is a China-based maker of single-use bioprocess bags and assemblies for use in the production of biopharmaceutical products. Major players in the single-use assemblies market are Avantor Inc., Corning Incorporated, Danaher Corporation, Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Saint-Gobain, Parker Hannifin Corporation, Repligen Corporation, Newage Industries, Antylia Scientific, Cole Parmer, Entegris Inc., GE Healthcare, and Pall Corporation. North America was the largest region in the single-use assemblies market in 2022.  The regions covered in single-use assemblies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the single-use assemblies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The single-use assemblies market consists of sales of 2D and 3D single-use assemblies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global single use assemblies market is segmented - 1) By Product Type: Filtration Assemblies, Bag Assemblies, Bottle Assemblies, Mixing System Assemblies 2) By Solution: Standard Solutions, Customized Solutions 3) By Application: Cell Culture And Mixing, Filtration, Storage, Sampling, Fill-Finish application 4) By End User: Biopharmaceutical And Pharmaceutical Companies, Contract Research And Contract Manufacturing Organizations, Academic And Research Institutes

Anemia and Other Blood Disorder Drugs refer to the medications or drugs that are used to treat anemia and other blood disorder diseases. It refers to a blood condition that develops when a medication prompts the body's immune system to begin attacking its own red blood cells. Hemolysis, a process that causes red blood cells to degrade earlier than usual, is brought on by this. The main types of anemia and other blood disorder drugs are iron deficiency anemia, chronic kidney disease anemia, sickle cell anemia, and aplastic anemia. Iron deficiency anemia is a common kind of anemia in which the blood does not contain enough healthy red blood cells. The oxygen-carrying red blood cells transport oxygen to the body's cells. The different types of anemia include microcytic (Low MCV), normocytic (Normal MCV), and macrocytic (High MCV) and involve various routes of administration such as oral, and injectable. It is distributed through hospitals pharmacies, online pharmacies, and pharmacy. The anemia and other blood disorder drugs market research report are one of a series of new reports from The Business Research Company that provides anemia and other blood disorder drugs market statistics, including anemia and other blood disorder drugs industry global market size, regional shares, competitors with anemia and other blood disorder drugs market share, detailed anemia and other blood disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anemia and other blood disorder drugs industry. This anemia and other blood disorder drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global anemia and other blood disorder drugs market size will grow from $11.14 billion in 2022 to $11.87 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global anemia and other blood disorder drugs market size is expected to grow to $14.80 billion in 2027 at a CAGR of 5.7%. The increasing prevalence of anemia among the global population acts as a strong driving factor for the market. Unhealthy lifestyles, changing dietary habits and increased stress levels increased the cases of anemia worldwide. For instance, anemia was found to be the most frequent disease in the elderly population (> 65 years of age), reaching a prevalence rate of around 17%. the World Bank reported that anemia is the 8th leading cause of disease among women and the young population. Growth in the prevalence rate of anemia drives the market. There has been an increase in the use of biologics for treating anemia and other blood disorders. Biologics are composed of protein, sugar, nucleic acids, or a combination of these substances or might be derived from living organisms like humans, animals, or microorganisms or that may contain components of living organisms. The growth in the use of biologics over the drugs restricts the market resulting in the decline of the number of drugs being used for the treatment of anemia& other blood disorders. For example, Hospira, a medical device and pharmaceutical company, submitted its first biologics license application to FDA for the approval of a drug that treats anemia. Moreover, the FDA approved the first Epoetin Alfa biosimilar for the treatment of anemia caused by chronic kidney disease, chemotherapy, or the use of zidovudine in patients with HIV infection. The increase in the use of biologics will hamper the growth of the market. Companies in the anemia and other blood disorder drugs market are collaborating with other companies to develop and commercialize a specific kind of drug by sharing the knowledge, technology, and cost. Such collaborations are also helpful to the companies in case of expiring licenses and a stringent regulatory environment. For example, in 2020, Akebia Therapeutics announced collaboration with Tobacco Inc. to treat adult patients with iron deficiency anemia. Another such example is, Akebia Therapeutics Inc. and Otsuka Pharmaceutical Co. Ltd. agreed to manufacture and commercialize vadadustat, an oral HIF stabilizer, used for the treatment of anemia. The anemia and other blood disorder drugs market is governed by several regulatory bodies that regulate their functioning by carrying out quality checks for that drug before it can be launched in the market. For instance, the U.S. Food & Drug Administration (FDA) requires every pharmaceutical company to get its drugs examined by the concerned authority. FDA sorts to a Risk Evaluation and Mitigation Strategy (REMS) for determining the safety and quality standards of the drug and grants approvals only if the standards are up to the mark. In October 2022, Pfizer, a US-based pharmaceutical company acquired Global Blood Therapeutics Inc. for an undisclosed amount. Through this acquisition, Pfizer expanded its portfolio in the development of drugs and brought various potential best-in-class treatments to people living with sickle cell disease. Global Blood Therapeutics Inc. is a US-based biotech company operating in anemia and other blood disorder drugs. Major players in the anemia and other blood disorder drugs market are Amgen Inc., GlaxoSmithKline PLC., Akebia Therapeutics, Bayer AG, Pfizer Inc., Regenbiopharma, Hoffmann-La Roche Ltd., Merck Sharp &Dohme Corp., Novartis AG and Janssen Pharmaceutical. North America was the largest region in the anemia and other blood disorder drugs market in 2022. Middle East is expected to be the fastest-growing region in the global anemia and other blood disorder drugs market during the forecast period. The regions covered in the global anemia and other blood disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anemia and other blood disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The anemia and other blood disorder drugs market consists of sales of folate analogues, multivitamin and mineral supplements, iron supplements, and erythropoiesis-stimulating agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global anemia and other blood disorder drugs market is segmented - 1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia 2) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy 3) By Route of Administration: Oral, Injectable 4) By Anemia Type: Microcytic (Low MCV), Normocytic (Normal MCV), Macrocytic (High MCV)

Gene editing is a technology that allows genetic material to change genetic code at a particular location in a genome. It involves cell line engineering, animal genetic engineering, and plant genetic engineering. The main technology types of gene editing are CRISPR, TALEN, and ZFN. CRISPR is a novel technology that allows geneticists and medical researchers to edit parts of the genome by removing, inserting, or modifying DNA sequences. The various applications include biotechnology, pharmaceuticals, and contract research organization that are used in animal genetic engineering, plant genetic engineering, and cell line engineering. The gene editing market research report is one of a series of new reports from The Business Research Company that provides gene editing market statistics, including gene editing industry global market size, regional shares, competitors with a gene editing market share, detailed gene editing market segments, market trends and opportunities, and any further data you may need to thrive in the gene editing industry. This gene editing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global gene editing market will grow from $6.35 billion in 2022 to $7.44 billion in 2023 at a compound annual growth rate (CAGR) of 17.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global gene editing market is expected to grow to $14.28 billion in 2027 at a CAGR of 17.7%. The rising infectious diseases act as one of the major drivers of the gene editing market. Gene editing techniques are used for the detection of infectious diseases such as HIV. Infectious diseases are caused by microorganisms like bacteria, viruses, fungi, and parasites. Gene therapy treats infectious diseases by blocking the replication of the infectious agent that causes the disease at the extracellular level. Gene editing introduces new genetic material into the cells of living organisms with the intention of treating diseases. Infectious diseases are constantly on the rise. For instance, according to the World Health Organization (WHO), infectious diseases kill more than 17 million people per year. In addition to that, according to the AP-NORC (a research initiative by the Associated Press and the University of Chicago) survey, out of 1,067 adults in the US surveyed, 71% are in favor of gene editing for the treatment of incurable, hereditary diseases such as Huntington’s disease and 67% of Americans support the use of gene editing to prevent diseases such as cancer. Ethical issues in general public with respect to gene editing is one of the major restraining factors for the market. Many researchers and ethicist have argued against gene editing due to different reasons such as off-target effect (edits in the wrong place), mosaicism (when only some of the cells carry the edits) and safety concerns. Some even argued that gene editing will lead to the creation of classes of individuals who will be genetically modified to be able to do things that a normal human being is not supposed to do according to the laws of nature. Due to these reasons, gene editing is still not considered to be safe and effective by many nations and international organizations. For instance, in 2020, as per the article published in TIME, scientists from Canada, China, France, Germany, Italy, New Zealand, and the USA have proposed a temporary prohibition on research on gene editing on human eggs, embryos, and sperms. Gene editing (also called genome editing) is a group of technologies that allow the researchers to change an organism's DNA by adding, removing or altering genetic material at particular locations in the genome. The emergence of advanced genome editing techniques is one of the major trends in the gene editing market. The new techniques in genome editing are relatively inexpensive and can be used in a variety of application areas such as improving the food supply in agriculture, rectifying specific genetic mutations in the human genome and preventing the spread of diseases. For instance, CRISPR-Cas9 is a gene editing technique and stands for Clustered Regularly Interspace Short Palindromic Repeats. The technique uses a strand of DNA as molecular scissors used to make cuts in DNA at specific points to make space to add new genomes. This technique is faster, cheaper, more accurate and efficient than other existing genome editing methods. Companies investing in CRISPR technology are Crispr therapeutics (CRSP), Intellia Therapeutics (NTLA), and Editas medicine. European regulatory framework divided gene therapy into two categories, germline gene therapy, and somatic gene therapy. In germ line gene therapy, modified genes will be passed on to next generations whereas it’s not the same case with somatic gene therapy. Current regulation by the EU has only allowed somatic gene therapy, therefore, germline gene therapy is banned. The European Medical Association provides guidelines on gene therapy for preparing market authorization application to obtain approval from the authority to carry on research and development activities in gene therapy. For instance, the EU provides guidance note on gene therapy medicinal product which is intended for use in humans, defines scientific principles and provide guidance for development and evaluation of gene therapy products. In December 2020, AnGes MG, Inc., a Japan-based biopharmaceutical company that offers nucleic acid drugs for patients with asthma, allergy, and rheumatism, acquired Emendo Bio, Inc. for $250 million.This acquisition will expand AnGes MG, Inc.'s pipeline and partnerships and introduce gene editing capabilities. Emendo Bio, Inc., a USA-based company that develops next generation gene editing tools for genetic disorders, addresses the current technological gaps for realizing the promise of gene therapy. Major players in the gene editing market are CRISPR, GenScript USA Inc., Horizon Discovery Group PLC., Integrated DNA Technologies, New England Biolabs, OriGene Technologies, Thermo Fisher Scientific, Merck KgaA, GenScript Corporation, Editas Medicine, Lonza Group, Sangamo, DNA 2.0, Bio RAD, Allele, Addgene, Sigma-Aldrich Corporation, Transposagen Biopharmaceuticals, Recombinetics, Precision Biosciences, Promega, Juno Therapeutics, Intellia Therapeutics, Qiagen, GE Healthcare Lonza, Cellectis, Dharmacon, AstraZeneca, and Agilent Technologies. North America was the largest region in the gene editing market in 2022. Western Europe was the second largest region in the global gene editing market. The regions covered in the global gene editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The gene editing market includes revenue earned by zinc-finger nucleases (ZFNs) and homing endonucleases or meganucleases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global gene editing market is segmented - 1) By Technology: CRISPR, TALEN, ZFN 2) By End Users: Biotechnology, Pharmaceutical, Contract Research Organization 3) By Application: Animal Genetic Engineering, Plant Genetic Engineering, Cell Line Engineering

The non-animal alternatives testing is testing products and services that do not involve testing on animals to determine the safety and efficacy of products and ingredients used in any industry sector. Non-animal alternative testing technologies include: in-vitro human cell and tissue cultures; organs-on-chips (OOCs); computer simulations and modelling (silico models); 3D bio-printing of tissues; and synthetic skin substitutes; as well as studies with human volunteers. These technologies replace animal testing in end-use industries including pharmaceuticals, medical devices, chemicals and pesticides, food, and others. The main methods of non-animal alternative testing are cellular assay, biochemical assay, in siliCo., and ex-vivo. A biochemical assay is an in vitro analytical process used to detect, quantify, and/or investigate the binding or activity of a biological molecule, such as an enzyme. The various technologies used include cell culture technology, high throughput technology, molecular imaging, omics technology, and other technologies. These are utilised by industries such as the pharmaceutical industry, cosmetics and household products, diagnostics, the chemical industry, and the food industry. The non-animal alternatives testing market research report is one of a series of new reports from The Business Research Company that provides non-animal alternatives testing market statistics, including non-animal alternatives testing industry global market size, regional shares, competitors with a non-animal alternatives testing market share, detailed non-animal alternatives testing market segments, market trends and opportunities, and any further data you may need to thrive in the non-animal alternatives testing industry. This non-animal alternatives testing market research report provides a comprehensive view of everything you require, including an in-depth analysis of the industry's current and future scenario. The global non-animal alternatives testing market grew from $1.78 billion in 2022 to $1.94 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The non-animal alternatives testing market is expected to grow from $2.9 billion in 2027 at a CAGR of 10.5%. The support from the government and non-governmental organizations boosts the growth of the non-animal testing market. The government organizations enforce laws and regulations, raise funds to support non-animal testing methods such as tests on human volunteers, and advanced computer-modeling techniques, and also fund studies with human volunteers. In order to support non-animal testing, People for the Ethical Treatment of Animals (PETA) India, in 2022, announced a grant of 7 lakh rupees in order to advance animal-free methods for toxicology testing. Similar research programs to promote non-animal testing procedures are also initiated by countries such as Denmark, Brazil, Germany, Switzerland, Australia, China, and Korea. The constant support from the government drives the growth of the non-animal testing market. Stringent regulations related to safety, efficacy, and quality are projected to act as a major challenge for players operating in the non-animal alternative testing market. All medicines and treatments go through stringent testing in the lab (pre-clinical research) and in small groups of patients (clinical research). The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) are the two main bodies regulating these novel therapies while getting them to market. Health Canada uses mAb specific guidelines from EMA or USFDA when necessary. The SAHPRA (South African Health Products Authority) biosimilar guideline has an annex on mAbs which focuses on non-clinical and clinical aspects. The Russian Federation has issued general product registration guidelines with very brief information about mAbs. Since it is a time-consuming process, it is considered one of the major hindering factors for the non-animal alternative testing market. OOCs (organs-on-chips) tool for testing is a major trend in the non-animal alternatives testing market. Organs-on-a-chips (OOCs) are miniature tissues and organs grown in-vitro that enable the modelling of human physiology and disease. OOCs are now being explored worldwide as tools for developing disease models and accurately predicting drug efficacies and toxicities. The advantages of OOCs over cell culture, animal models, and human clinical trials have captured the attention of both the medical and pharmaceutical communities, focusing on developing targeted therapies. For instance, in April 2020, researchers at the Massachusetts Institute of Technology (MIT) in the US developed a new model for Organs-on-a-Chip to develop treatments for inflammatory diseases and afflictions. Organs-on-a-chip consist of millions of cells formed on a platform to replicate the functions of different organs and can be used as an instrument in analysing and creating new treatments for complex diseases without the use of animals for testing. Major players in the non-animal alternatives testing are MatTek Corporation, Cyprotex, Emulate Inc., BioIVT, Bio-Rad Laboratories, GE Healthcare, SGS SA, BioIVT, Abbott Laboratories and Gentronix Limited. North America was the largest region in the non-animal alternatives testing in 2022. Western Europe was the second-largest region in the global non-animal alternatives testing market report. The regions covered in the global non-animal alternatives testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The non-animal alternatives testing market consists of revenue earned by that perform organs-on-chips (OOCs) technology, and 3D bio-printing of tissues among others. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for specified geography are consumption values – that is, they are revenues generated by organisations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales along the chain or as part of other products. The global non-animal alternatives testing market is segmented - 1) By Technology: Cell Culture Technology, High Throughput Technology, Molecular Imaging, Omics Technology, Other Technologies 2) By Method: Cellular Assay, Biochemical Assay, In SiliCo., Ex-vivo 3) By End-User: Pharmaceutical Industry, Cosmetics & Household Products, Diagnostics, Chemicals Industry, Food Industry

Cell culture refers to the growth of human, plant, or animal cells in a lab, as well as the growth of microorganisms like bacteria and yeast. Cell cultures can be used for research, medication testing, and infection diagnosis. The cells may come from multicellular eukaryotes, established cell strains, established cell lines, or any combination of these. The main types of cell culture are primary cell culture, secondary cell culture, and cell line. Primary cell cultures are those that develop from tissue explants or specific cells extracted from the source tissue. The different media include natural and artificial ones and are used in stem cell technologies, cancer research, biopharmaceuticals, tissue engineering, regenerative medicine, and others. The cell culture market research report is one of a series of new reports from The Business Research Company that provides cell culture market statistics, including cell culture industry global market size, regional shares, competitors with a cell culture market share, detailed cell culture market segments, market trends and opportunities, and any further data you may need to thrive in the cell culture industry. This cell culture market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cell culture market grew from $22.49 billion in 2022 to $24.94 billion in 2023 at a compound annual growth rate (CAGR) of 10.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cell culture market is expected to grow from $38.18 billion in 2027 at a CAGR of 11.2%. The rise in demand for cell therapy is expected to drive the cell culture market. In cell therapy, viable cells are injected or implanted into a patient's body to cure a medicinal disease. Cell culture is a vital step in any cell-based therapy. According to the Cancer Research Institute (CRI), there are about 1,483 active cell therapies in development in 2020, compared to 1,011 in 2019. Cell culture is used in the development, manufacture, and commercialization of cell therapies and holds the potential to revolutionise the healthcare industry for the treatment of various diseases. Hence, a surge in the demand for cell therapy aids in the growth of the cell culture market. The lack of skilled professionals is expected to hinder the cell culture market’s growth. The consequence of having unskilled workers can also be detrimental to the bottom line of a company, as even a small batch error can cost an organisation millions of dollars. The regulatory agency that issues the facility's licence requires an annual report that includes all failed batches, and if the failure rate is higher than 5%, the plant may be at risk of losing its ability to sell its drug. Furthermore, in February 2022, the U.S. Bureau of Work Statistics estimated that the pandemic cost the labour force close to 8 million skilled-labor positions. In the sectors in charge of the majority of the nation's transportation, construction, and mechanical needs, nearly half of the vacancies have been filled, but about 4 million still exist. The lack of talent is expected to adversely impact the growth of the cell and gene therapy industry, thereby restraining the growth of the cell culture market. The development of products for 3D cell culture by the companies operating in the cell culture market is gaining significant popularity. A 3D cell culture is an artificially created environment in which biological cells are permitted to grow or interact with their surroundings in all three dimensions, similar to how they would in a living organism. For instance, in July 2020, Rigenerand, an Italian company engaged in the production of innovative cell-based technology products for regenerative medicine and oncology, launched a 3D bioreactor called the VITVO handheld bioreactor to offer increased usability, sizing, a closed system, and flexibility for 3D cell culture technologies. Similarly, Jellagen, a UK-based marine biotechnology company, launched JellaGel, a jellyfish collagen hydrogel, suitable for 3D cell culture and tissue engineering. Danaher, a Fortune 500 science and technology company based in the United States, paid $21.4 billion for General Electric Life Sciences' biopharma business in March 2020.As a part of Danaher, the company is to be called Cytiva and will be a standalone operating company within Danaher's Life Sciences segment. GE Biopharma’s offerings included cell culture media, single-use technologies, process chromatography hardware & consumables, development instrumentation and consumables, and service. Major players in the cell culture market are Thermo Fisher Scientific Inc., Corning, Inc., Becton, Dickinson, and Company, Eppendorf AG, Merck KGAA, Lonza Group AG, Sartorius AG, Promocell GmbH, Danaher, and Sartorius. North America was the largest region in the cell culture market in 2022. The Middle East is expected to be the fastest growing region in the global cell culture market during the forecast period. The regions covered in the global cell culture market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cell culture market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cell culture market includes revenues earned by entities by diagnosing infections, testing new drugs, and conducting research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain or as part of other products. The global cell culture market is segmented - 1) By Type: Primary Cell Culture, Secondary Cell Culture, and Cell Line 2) By Media: Natural, Artificial 3) By Applications: Stem Cell Technologies, Cancer Research, Biopharmaceutical, Tissue Engineering & Regenerative Medicine, Other Applications

Fetal bovine serum refers to a typical element of animal cell culture media that is utilised to support the growth of eukaryotic cells cultured in vitro. It is obtained by harvesting bovine foetuses from pregnant cows who were about to be slaughtered. FBS is frequently obtained with a cardiac puncture without the use of any type of anaesthesia. The main types of fetal bovine serum are charcoal stripped, chromatographic, dialyzed fetal bovine serum, exosome depleted, stem cell, others. Charcoal-stripped fetal bovine serum has activated carbon that helps lower levels of lipophilic compounds such as hormones, growth factors, and steroids and is used to conduct receptor or estrogen related studies. Dialyzed fetal bovine serum has reduced concentration of low molecular weight components such as nucleotides, amino acids, hormones, salts and various small proteins in serum and is used in cell culture systems requiring a more defined environment of small molecules. Exosome depleted fetal bovine serum isolates exosomes from cultured cells without the complication of bovine exosomes that are present in conventional FBS and is used for research on exosomes. The fetal bovine serum is used in drug discovery, cell culture media, in vitro fertilization, human and animal vaccine production, diagnostics, others. Fetal bovine serum is used in various sectors including research and academic institutes, biotechnology and pharmaceutical industry, others. The fetal bovine serum market research report is one of a series of new reports from The Business Research Company that provides fetal bovine serum market statistics, including fetal bovine serum industry global market size, regional shares, competitors with a fetal bovine serum market share, detailed fetal bovine serum market segments, market trends and opportunities, and any further data you may need to thrive in the fetal bovine serum industry. This fetal bovine serum market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global fetal bovine serum market size grew from $1010 million in 2022 to $1067.44 million in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The fetal bovine serum market size is expected to grow to $1419.98 million in 2027 at a CAGR of 7.4%. The increase in demand for biopharmaceuticals is expected to drive the growth of the fetal bovine serum market in the forecast period. A biopharmaceutical is a medicinal product that is derived from biological sources such as animals, humans, and microorganisms using biotechnology. Fetal bovine serum (FBS) is the most widely used substitute for animal cell culture media. Pharmaceutical firms, diagnostic laboratories, and researchers rely heavily on FBS for much of their cell culture requirements in biologics research. The global biologics market is expected to increase from $253.4 billion in 2020 to $420.5 billion by 2025. Therefore, the rising demand for biopharmaceuticals propels the growth of the fetal bovine serum market. Increasing collaborations between companies and research intuitions is a key trend gaining popularity in the fetal bovine serum market. Major companies are collaborating for increasing production capabilities, expanding market share and developing new products. For instance, US based GE Healthcare collaborated with New Zealand based Oritain for developing an independent test that can confirm the country of origin of fetal bovine serum (FBS) which would help biomanufacturing entities as FBS used in different countries pose different risk levels for virus contamination. Sartorius, a German-based life science research and biopharmaceutical company acquired Biological Industries for $53.67 million. Through this acquisition, Sartorius expanded cell culture media and complementing the product portfolio for the users in the growing advanced therapies market in the majority portion of Biological Industries. Biological Industries is an Israel-based chemical and biotechnology company that provides fetal bovine serum for mammalian cell culture. Major players in the fetal bovine serum market are Sartorius AG, GE Healthcare, PAN- Biotech, Thermo Fisher Scientific Inc., Biowest, Bio-Techne, Rocky Mountain Biologicals Inc., Merck KGaA, TCS Biosciences Ltd., Bovogen Biologicals Pty Ltd., Tissue Culture Biologicals, Atlanta Biologicals Inc., Atlas Biologicals, Acess Biologicals, Animal Technologies Inc., Nucleus Biologics, Corning Incorporated, J R Scientific Inc., Cytiva, Axil Scientific Pte Ltd., and Moregate Biotech. North America was the largest region in the fetal bovine serum market in 2022. Asia-Pacific recorded the fastest growth during the forecast period. The regions covered in the fetal bovine serum report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the Fetal Bovine Serum market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The fetal bovine serum market consists of sales of Ultra-low IgG, ES Cell, MSC and Exosome-Depleted. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global fetal bovine serum market is segmented - 1) By Product: Charcoal Stripped, Chromatographic, Dialyzed Fetal Bovine Serum, Exosome Depleted, Stem Cell, Other Products  2) By Application: Drug Discovery, Cell Culture Media, In Vitro Fertilization, Human and Animal Vaccine Production, Diagnostics, Other Applications 3) By End-User: Research and Academic Institutes, Biotechnology and Pharmaceutical Industry, Other End-Users

Single-use bioprocessing refers to bioprocessing equipment designed to be used only once and then discarded. These are generally made of plastic components that are sterilized using gamma radiation. It can help save cleaning time, water, and energy consumption. The single-use bioprocessing is used throughout the bioproduction workflow with minimum risk of cross-contamination. The main types of products in single-use bioprocessing market are single-use media bags and containers, single-use assemblies, single-use bioreactors, disposable mixers, and others. Single-use media bags and containers market consists are used for containing sterile media, cell cultures, sera, buffers, and reagents. Single-use media bags and containers are sterile containers that can be only used once and then discarded. The different workflows include upstream, fermentation, and downstream. The various applications are filtration, storage, cell culture, mixing, and purification. It is used by biopharmaceutical and pharmaceutical companies, contract research organizations and contract manufacturing organizations (CROs and CMOs), academic and research institutes. The single-use bioprocessing market research report is one of a series of new reports from The Business Research Company that provides single-use bioprocessing market statistics, including single-use bioprocessing industry global market size, regional shares, competitors with a single-use bioprocessing market share, detailed single-use bioprocessing market segments, market trends and opportunities, and any further data you may need to thrive in the single-use bioprocessing industry. This single-use bioprocessing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global single use bioprocessing market size grew from $18.33 billion in 2022 to $21.88 billion in 2023 at a compound annual growth rate (CAGR) of 19.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The single use bioprocessing market size is expected to grow to $43.78 billion in 2027 at a CAGR of 18.9%. The surge in demand for biopharmaceuticals is expected to propel the growth of the single-use bioprocessing market going forward. Biopharmaceuticals are medicines made from living cells or organisms. Single-use bioprocessing systems are commonly used in biopharmaceutical manufacturing for increasing productivity, saving costs, and safe disposal of waste. For instance, according to a report by the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based pharmaceutical trade association, 2020, biopharmaceutical production in Europe reached $315.8 billion in 2020, up from $298.7 billion in 2019. Therefore, the increasing demand for biopharmaceuticals is driving the growth of the single-use bioprocessing market. Technological advancements are a key trend gaining popularity in the single-use bioprocessing market. Major companies operating in the single-use bioprocessing market are introducing new technologies to sustain their position. For instance, in February 2020, Applikon Biotechnology, a Netherlands-based upstream bioprocess equipment manufacturer, launched the AppliFlex ST lab-scale bioreactor. It is a single-use fully customizable and scalable bioreactor made using 3D printing technology that is uniquely configured to each process, including custom impeller design, inlets, outlets, and various port connections. It helps to provide multiple options, such as impellers in helical, and hydrofoil. In June 2021, Avantor Inc., a US-based chemicals and materials manufacturer acquired RIM Bio for an undisclosed amount. The acquisition would help Avantor to better serve the customers by expanding the single-use manufacturing portfolio in the AMEA region. RIM Bio is a China-based manufacturer of single-use bioprocess bags and assemblies for biopharmaceutical manufacturing. Major players in the single use bioprocessing market are GE Healthcare, Eppendorf AG, Corning Incorporated, Thermo Fisher Scientific Inc., Sartorius AG, JM BioConnect, Merck KGaA, Pall Corporation, Kuhner AG, PBS Biotech Inc., Entegris Inc., Distek Inc., ABEC Inc., Able Corporation, and Biott Corporation, Solida Biotech GmbH, OmniBRx Biotechnologies Pvt Ltd., Satake Chemical Equipment Mfg. Ltd., Stobbe Pharma GmbH, Celltainer Biotech BV, and Cellexus. North America was the largest region in the single-use bioprocessing market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single use bioprocessing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the single use bioprocessing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The single-use bioprocessing market includes revenues earned by entities by bioreactors, tangential-flow filtration devices, depth filters, disposable filter cartridges, media bags and containers, mixing systems, tubing assemblies and sampling systems. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global single use bioprocessing market is segmented - 1) By Product: Single-Use Media Bags And Containers, Single-Use Assemblies, Single-Use Bioreactors, Disposable Mixers, Other Products. 2) By Workflow: Upstream, Fermentation, Downstream 3) By Application: Filtration, Storage, Cell Culture, Mixing, Purification 4) By End User: Biopharmaceutical And Pharmaceutical companies, Contract Research Organizations And Contract Manufacturing Organizations (CROs and CMOs), Academic and Research Institutes